CASBF (CanSino Biologics) Cash per Share: $1.51 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASBF CanSino Biologics Inc CASBF
65 GF Score
Price $3.15
GF Value $8.77
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is CanSino Biologics Cash per Share?

CanSino Biologics CASBF +20.96% 65 Cash per Share is $1.51 as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $8.77 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). CanSino Biologics's Cash per Share for the quarter that ended in Dec. 2025 was $1.51.

CanSino Biologics  (OTCPK:CASBF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

CanSino Biologics Cash per Share Related Terms

CanSino Biologics Cash per Share Historical Data

* Premium members only.

The historical data trend for CanSino Biologics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Cash per Share Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.94 3.45 2.33 1.77 1.51

CanSino Biologics Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Jun25 Sep25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 1.77 1.83 1.40 1.51
CASBF
65GF Score
CanSino Biologics Inc CASBF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanSino Biologics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

CanSino Biologics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=373.143/247.04
=1.51

CanSino Biologics's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=373.143/247.04
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $1.51 mean?
CanSino Biologics (CASBF) has a Cash per Share of $1.51 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for CanSino Biologics and its competitors.
Is CanSino Biologics' Cash per Share too high?
CanSino Biologics' current Cash per Share is $1.51. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Cash per Share compare to ZTS and UTHR?
CanSino Biologics' Cash per Share of $1.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Drug Manufacturers company?
A good Cash per Share depends on the Drug Manufacturers industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for CanSino Biologics and its competitors. CanSino Biologics's current Cash per Share is $1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.77, compared to a current price of $3.15 — trading 64.1% below its estimated fair value. The current Cash per Share is $1.51. CanSino Biologics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Cash per Share is $1.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CanSino Biologics (CASBF) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of $3.15 is trading 64.1% below its estimated GF Value™ of $8.77. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for CASBF:

  • Cash per Share: $1.51
  • GF Value™: $8.77 vs. price of $3.15 (64.1% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score

Get the complete analysis for CASBF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.15
Price
$8.77
GF Value